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Human genetic studies have revealed that the T minor allele of single nucleotide polymorphism
rs7903146 in the transcription factor 7-like 2 (TCF7L2) gene is strongly associatedwith an increased
risk of diabetes by 30%–40%. Molecular and clinical studies are of great importance for under-
standing how this unique variation in TCF7L2 influences type 2 diabetes (T2D) onset and progres-
sion. At the molecular level, some studies have been performed in diabetic mice and pancreatic
islets fromhealthy human donors.Whereas TCF7L2mRNA levels are up-regulated in islets, protein
levels are down-regulated. We performed studies on TCF7L2 splicing, mRNA expression, and
protein levels in immortalized human lymphocytes from nondiabetic individuals and T2D patients
carrying the C/C or the at-risk T/T genotype. Our results show differential expression of TCF7L2
splice variants between nondiabetic and T2D patients carrying the at-risk genotype, as well as
differences in protein levels. Therefore, we investigated the regulation of splice variants, and our
results propose that splicing of exon 4 is under control of the serine-arginine–rich factor trans-
former 2  (TRA2B). Finally, we studied the endoplasmic reticulum stress pathways, looking for a
posttranslational explanation. We saw a shift in the activation of these pathways between non-
diabetic individuals and T2D patients carrying the at-risk genotype. These results suggest that, in
human immortalized lymphocytes carrying the at-risk T/T genotype, first the differential expres-
sion of TCF7L2 splice variants implies a regulation, at least for exon 4, by TRA2B and second, the
differential protein levels between both T/T carriers point to a different activation of endoplasmic
reticulum stress pathways. (Molecular Endocrinology 28: 1558–1570, 2014)
Type 2 diabetes (T2D) prevalence has reached epidemicproportions throughout the world, and it is the most
common metabolic disorder in Western countries associ-
ated with obesity (1). T2D is a complex disease and in-
volves the interplay between environmental risk factors
and predisposing genetic backgrounds.
To date, several genome-wide association studies have
identified the genes most frequently associated with T2D
(2). One of the most relevant genes among them is the
transcription factor 7-like 2 (TCF7L2, previously known
as T-cell factor [TCF] 4), in which a single nucleotide
polymorphism (SNP), rs7903146, in intron 4, consisting
of a change from a cytosine (C) to a thymine (T) nucleo-
tide, has been strongly correlatedwith an increased risk of
developing T2D (3). TCF7L2 is a ubiquitous protein that
belongs to a family of TCF/lymphoid enhancer factor
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transcription factors. The T2D risk–associated T/T geno-
type is present approximately in 7%–10% of the nondi-
abetic population, whereas its prevalence increases up to
14%–20% of the total diabetic population (3–5).
The human TCF7L2 gene is encoded by 17 identified
exons, 5 ofwhich are subject to alternative splicing (exons
4, 13, 14, 15, and 16) (6). To date, extensive work has
been done to evaluate the splicing diversity and expres-
sion of TCF7L2 in a broad range of human and mouse
tissues, including not only pancreatic islets but also liver,
gut, brain, and adipose tissues among others. Prokunina-
Olsson et al (7) analyzed the TCF7L2 splicing isoform
pattern in different types of human tissue (pancreas, pan-
creatic islets, colon, liver, monocytes, skeletal muscle,
subcutaneous adipose tissue, and lymphoblastoid cell
lines) and observed a tissue-specific pattern of alternative
splicing. In addition, Prokunina-Olsson and Hall (8) fur-
ther characterized the TCF7L2 3 end splicing variants in
different human tissues, observing that these transcripts
may share neuroendocrine functions important for brain,
gut, and pancreatic islets. Recently Shao et al (9) found
that in gut endocrine L-cell lines, TCF7L2 controls tran-
scription of the proglucagon gene (gcg). They generated
transgenic mice that express dominant-negative TCF7L2
specifically in gcg-expressing cells, concluding that
TCF7L2 and Wnt signaling control gut and brain gcg
expression and glucose homeostasis (9). In 2012, Oh et al
(10) observed that the expression of medium and short
isoforms of TCF7L2 in liver was greatly diminished in
both diet-induced and genetic mouse models of insulin
resistance. They found that nuclear isoforms of TCF7L2
are capable of binding to promoters of gluconeogenic
genes, suggesting a crucial role for TCF7L2 in hepatic
glucose metabolism (10). Recently, Neve et al (11) ad-
dressed the impact of TCF7L2 isoforms on hepatocyte
nuclear factor 4 (HNF4) and on the regulation of glu-
coneogenic genes in humans. They described different ex-
pression levels of the TCF7L2 3 end splicing variants in
HepG2 cells and in liver, suggesting that these transcripts
play a role in the pathophysiology of type 2 diabetes.
Moreover, they showed that 2 TCF7L2 splicing variants,
lacking exon 4 and including extranucleotides of exon 7
but with different carboxyl terminal exons, interact with
HNF4 (11). Some of these studies have revealed a splic-
ing similarity between pancreatic islets and blood lym-
phocytes, although TCF7L2 expression is lower in the
latter tissue (7, 12).
Focusing on pancreatic islets, biological studies have
clearly demonstrated the role of TCF7L2 in insulin secre-
tion and in the survival of isolated pancreatic islets (13,
14). However, the molecular mechanisms describing how
the genetic variation of TCF7L2 leads to altered biologi-
cal function are still largely controversial. TCF7L2 SNPs
could lead to impaired TCF7L2 function and increased
diabetes risk by changing the distribution ofmRNA splice
variants (7, 12, 13, 15, 16).
Splicing is the process by which exons are joined to-
gether by the removal of introns to produce a mature
mRNA, which can then be further translated. Splicing is
usually constitutive. However, alternative splicing has
also been observed, in which the exons may be combined
in some other way, introducing new coding information
intomRNAs. Alternative splicing affects the vastmajority
of human genes (90%) (17). Consequently, multiple
mRNAs and protein isoforms are produced from a rela-
tively small number of genes, such as TCF7L2, thus be-
coming one of the main sources of protein diversity (18,
19). Because of the relevance of alternative splicing, this
molecular mechanism is highly regulated by both cis-reg-
ulatory sequences and trans-acting factors (Supplemental
Figure 1C).Cis-regulatory sequences include exonic splic-
ing enhancers (ESEs), exonic splicing silencers, intronic
splicing enhancers(ISEs), and intronic splicing silencers,
depending on their locations and on how they affect the
selection of a splice site. On the other hand, trans-acting
factors act through binding to splicing enhancers and si-
lencers and include members of well-characterized serine-
arginine–rich (SR) proteins (20) and heterogeneous nu-
clear ribonucleoproteins (hnRNPs (21), as well as tissue-
specific factors such as FOX (22), NOVA (23), nPTB, and
PTB (24). The interplay between the different compo-
nents of the spliceosome specifically defines the alterna-
tive splicing of each exon.
Once the splicing is over, the mRNA must be trans-
lated into protein, but the newly produced proteins are
not immediately functional. To become properly func-
tional, they have to enter the endoplasmic reticulum (ER),
where they are folded and assembled. To ascertain fidelity
in protein folding, cells regulate the protein-folding ca-
pacity in the ER according to their needs. The ER re-
sponds to unfolded proteins in its lumen (ER stress) by
activating intracellular signal transduction pathways that
coordinate adaptive and apoptotic responses, collectively
termed the unfolded protein response (UPR). The most
ER-proximal regulators of the UPR consist of a set of
transmembrane ER-resident proteins, including inositol-
requiring protein 1 (IRE1), protein kinase receptor–like
endoplasmic reticulum kinase (PERK), and activating
transcription factor 6 (ATF6). These proteins bear do-
mains protruding into the ER lumen, which sense ER
stress, coupled to cytosolic effector domains. Together,
these 3 mechanistically distinct branches of the UPR reg-
ulate the expression of numerous genes that maintain ho-
meostasis in the ER or induce apoptosis, if ER stress re-
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mains unmitigated. There is accumulative evidence
implicating prolonged ER stress in the development and
progression of many diseases, including T2D (25, 26).
Transcription and translation of the TCF7L2 gene are
oppositely regulated in T2D (14, 27). The possible expla-
nation for this opposing regulation at RNA and protein
levels is that increased mRNA expression reflects several
TCF7L2 transcripts. On the translational level, these
transcripts could encode fewer or different protein iso-
forms with different effects on target cells. Therefore, in
the present study we characterized the expression of the
different splice variants and protein levels of TCF7L2 in
human immortalized lymphocytes, distinguishing be-
tween nondiabetic and T2D patients carrying the C/C or
the at-risk T/T genotype.
Materials and Methods
Genetic analysis and manipulations were performed after in-
formed written consent was received from the individuals in the
study, upon approval by the institutional ethics committee.
Study samples and clinical characteristics
Caucasian Spanish participants recruited were 110 nondia-
betic individuals and 110 T2D patients. SNP rs7903146 was
genotyped in all participants to find the carriers of the T/T
at-risk genotype. Only 7 of 110 nondiabetic subjects were ho-
mozygous T/T carriers, consistent with results of previous epi-
demiological studies, in which 7%–10% of the population car-
ried the at-risk genotype. After genotyping, 28 subjects were
selected (14 nondiabetic control subjects and 14 T2D patients,
each groupwith 7 individuals homozygous for theC allele or the
T allele), matched by body mass index and age and sex distri-
bution (Table 1). Diabetes was diagnosed by following the
American Diabetes Association recommendations (28, 29), and
none of the control subjects had diabetes or prediabetes.
Study group definition
To perform the experiments, we delimited 4 different groups
based on the SNP rs7903146 genotype and the presence or
absence of diabetes. Thus, we designated the nondiabetic indi-
viduals carrying the nonrisk C/C genotype as the control group,
because this group does not carry the at-riskT/T genotype or the
diabetic background. Furthermore, we designated the T2D pa-
tients carrying the at-risk T/T genotype as our study group,
because they present both the risk genotype and diabetes. Fi-
nally, we decided to include another 2 groups, to help us discern
between the diabetic background (T2D patients carrying the
nonriskC/C genotype) and the genetic background (nondiabetic
individuals carrying the at-risk T/T genotype).
Immortalization of human B lymphocytes and
cell culture
Lymphocytes were immortalized by the Biobank of the In-
stitut d’investigacions Biomèdiques August Pi i Sunyer (Barce-
lona, Spain). In brief, lymphocytes were isolated from whole
blood by gradient centrifugation with Ficoll, and immortaliza-
tion was induced by Epstein-Barr virus infection. Immortalized
lymphocyte cultures were maintained with RPMI 1640medium
without glucose and glutamine (Biosera) supplemented with
10% fetal bovine serum, penicillin-streptomycin, and L-glu-
tamine (HyClone).
Stimulated cell culture
Immortalized lymphocytes were cultured under nonphysi-
ological conditions. Insulin was added to 1.5 million immor-
talized lymphocytes at a concentration of 100 nM, and con-
currently we cultured the cells with an elevated glucose
concentration (25 mM). In both experiments, cells were in-
cubated at 37°C overnight.
Cell transfection
Immortalized lymphocytes were seeded at a density of 2 
105 cells/well and split onto nontreated 24-well plates (Costar).
Cells were transfected with 100 nM ON-TARGETplus human
TRA2B small interfering RNA (siRNA) or ON-TARGETplus
non-targeting pool siRNA (Dharmacon) using Metafectene Pro
(Biontex Laboratories GmbH) as the transfection reagent, fol-
lowing the manufacturer’s instructions.
RNA isolation
Total RNA was extracted according to the manufacturer’s
instructions using an RNeasy Mini plus kit (Qiagen). RNA
quantity and puritywere determined by aNanoDrop 1000 spec-
trophotometer (Thermo Fisher Scientific), and the RNA was
electrophoresed in a 1.5% agarose gel (1  Tris borate–EDTA
[TBE] buffer in RNase-free water) to exclude degradation of
RNA and contamination with DNA.
cDNA synthesis
The reverse transcription reaction was performed using a
commercially available set (High Capacity cDNAReverse Tran-
scription Kit; Applied Biosystems). cDNA was prepared from 1
g of mRNA, with random hexamer primers, according to the
manufacturer’s instructions. The resulting cDNAwas diluted to
a final concentration of 5 ng/L and stored at 20°C.
Primers and amplicon design
To avoid amplification of contaminating genomic DNA, at
least one of the primers was designed over exon-exon junctions,
and the forward primer was designed to hybridize to one exon
and the reverse primer to another exon, producing an amplicon
Table 1. Brief Summary of Clinical and Genetic
Features of the Patient Cohort
Male/
Female
Age, y
Body Mass
Index, kg/m2
Mean SEM Mean SEM
Non-T2D C/C 5/2 52.29 4.65 24.96 1.01
Non-T2D T/T 5/2 59.29 3.40 27.55 0.68
T2D C/C 5/2 58.86 3.60 27.25 1.44
T2D T/T 5/2 61.14 3.38 27.25 1.68
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with an optimal size between 85 and 150 bp (Supplemental
Table 1).
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed on an ABI Prism 7900HT se-
quence detection system (Applied Biosystems) with a 384-well
reaction plate. All amplifications were carried out at least in
duplicate. The reaction was performed using SYBR Premix Ex
Taq (Tli RNase H Plus) (Takara-Clontech) in a 10-L total
volume. In brief, 2 L of diluted cDNA template and 8 L of
reaction mixture consisting of 5 L of SYBR Premix Ex Taq
(2) and 0.2 L of ROX reference dye (50), 0.5 L of each
forward and reverse primer (10 M), and 1.8 L of nuclease-
freewaterwere run using a standard cycling program as follows:
95°C for 30 seconds, followed by 40 cycles of 95°C for 5 sec-
onds and 60°C for 34 seconds. Dissociation curve analysis of the
PCR amplicons was performed at the end of amplification to
verify single product amplification.
The relative quantification of gene expression in each sample
was analyzed using SDS software version 2.4 (Applied Biosys-
tems). The Ct value for each sample was measured in duplicate,
and the average was normalized against the endogenous control
-actin to determine the Ct value. The Ct values were then
standardized against the calibrator’s Ct values (C/C nondia-
betic) to yield the Ct, and the relative quantification was
calculated as 2Ct (30).
The analyzed splice variants of TCF7L2 and TRA2B were
intranormalized with their own total mRNA expression.
Apoptosis measurement
The caspase activity was measured by the commercial
Caspase-Glo 3/7 assay (Promega) following the manufacturer’s
instructions. We cultured 15 000 cells/well in 100 L of RPMI
1640 medium. To induce apoptosis in the positive controls, we
added 10 Mstaurosporine. The caspase activity was measured
by luminescence, using a Veritas microplate luminometer
(Turner Biosystems) with GloMax software at 60 minutes.
Western blot
Extracts from cultured immortalized lymphocytes were
prepared with lysis buffer (PBS, 50 mM Tris, 5 mM EDTA,
150 mM NaCl, 1% Triton X-100, 1 protease inhibitors,
and 1 phosphatase inhibitors) or radioimmunoprecipita-
tion assay buffer (50 mM Tris-HCl, 150 mM NaCl, 10%
sodium deoxycholate, 1% NP-40, 1 mM EDTA, 1 mM
Na3VO4, 1 mM polyvinylidene difluoride, and 1 mM NaF).
Protein lysates in aliquots of 20 g were separated by Nu-
PAGE Novex 10% Bis-Tris gels (Invitrogen, CA, USA) and
transferred to a polyvinylidene fluoride membrane. Primary
antibodies used were the following: TCF7L2 (TCF4) (1:
25 000; Abcam), chaperone BiP (1:1000) (Santa Cruz Bio-
technology, Inc.), phosphor-eIF2 (1:1000; Cell Signaling
Technology), CHOP (1:1000; Cell Signaling Technology),
and the housekeeping actin (Sigma-Aldrich).
In silico analysis of splicing factor binding sites
Putative binding sites surrounding the TCF7L2 alternatively
spliced exons and intron boundaries were analyzed using 2 dif-
ferent software programs: SFmap (http://sfmap.technion.ac.il)
and SpliceAid-F (http://srv00.ibbe.cnr.it/SpliceAidF/).
Statistical analyses
Statistical analyses were performed with GraphPad Prism
(version 5; GraphPad Software, Inc.) and the Statistical Package
for the Social Sciences (SPSS version 20; IBM Corporation).
Data were analyzed with the Shapiro-Wilk test to assess the
assumption of normality. For comparison of differences be-
tween the 4 groups of patients, ANOVA followed by a post hoc
Tukey analysis was applied. In the case of deviation from a
normal distribution, we used the Kruskal-Wallis andDunnmul-
tiple comparison tests. For the cell transfection comparison,
statistical significance was tested by the Mann-Whitney U test.
A value of P .05 was considered statistically significant. Data
are presented as means  SEM.
Results
Differential expression of the TCF7L2 splice
variants and protein, depending on the
at-risk genotype
It has been demonstrated thatTCF7L2 presents a com-
plex alternative splicing pattern (Supplemental Figure
1A), but to date, the splice variants that are preferentially
expressed by the T2D risk-associated genotype in T2D
patients and healthy carriers remain unknown. There-
fore, we performed qRT-PCR to measure the expression
of the TCF7L2 splice variants in immortalized B lympho-
cytes from the 4 groups studied (Supplemental Figure 1B).
We focused on exon 4, the 9 extra nucleotides at the end
of exon 7, the 12 extra nucleotides at the beginning of
exon 9, and the 3 end variants, which comprise exons 12
to 17 (Figure 1A).
Alternative splicing of exon 4 has been extensively
studied, because it has been thought to be associated with
the at-risk T/T genotype (16). Our results showed that
T2D patients carrying the at-riskT/T genotype (T/TT2D)
had a statistically significant decrease in exon 4 exclusion
(P 	 .038 vs T2D patients carrying the C/C genotype,
hereafter C/C T2D). On the other hand, nondiabetic in-
dividuals carrying the same at-risk T/T genotype (hereaf-
ter T/T non-T2D) showed a statistically significant in-
crease in exon 4 exclusion (P 	 .046 vs nondiabetic
individual carrying the C/C genotype, hereafter C/C non-
T2D) (Figure 1, B and C, respectively, and Supplemental
Table 2). Furthermore, the differences were higher in the
splicing of exon 4 between nondiabetic individuals and
T2D patients carrying the at-risk T/T genotype (P 	
.0001).
The complex splicing pattern covering the TCF7L2
gene involves the inclusion/exclusion of 9 extra nucleo-
tides at the end of exon 7 and 12 extra nucleotides at the
beginning of exon 9. On one hand, the expression pattern
in T2D patients carrying the at-risk T/T genotype showed
a statistical decrease in the exclusion of the extra nucleo-
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tides of exon 7 (P	 .003 vsC/CT2D and P	 .012 vsC/C
non-T2D), whereas nondiabetic individuals carrying the
same at-risk T/T genotype did not show statistical differ-
ences (Figure 1, D and E, respectively, and Supplemental
Table 2). On the other hand, nondiabetic individuals and
T2D patients carrying the at-risk T/T genotype showed a
statistically significant increase in the exclusion of the
extra nucleotides of exon 9 (P 	 .021 vs C/C non-T2D
and P 	 .003 vs C/C T2D, respectively) (Figure 1, F and
G, respectively, and Supplemental Table 2).
Regarding the splice variants covering the 3 end of
TCF7L2, the expression analysis showed a significant in-
crease in the variant, including the junction between ex-
ons 12 and 17 in T2D patients carrying the at-risk T/T
genotype (P 	 .011 vs C/C T2D, P 	 .015 vs C/C non-
T2D and P 	 .004 vs T/T non-T2D) (Figure 1H and
Supplemental Table 2). The expression of the splice vari-
ants including exons 12 to 15 or exons 12, 13, and 17
were significantly increased in nondiabetic individuals
carrying the at-risk T/T genotype (P	 .042 and P	 .035
vs C/C non-T2D, respectively) but statistically decreased
in T2D patients with the same at-risk T/T genotype (P 	
.042 and P 	 .035 vs C/C T2D, respectively) (Figure 1, I
and J, respectively, and Supplemental Table 2). Neverthe-
less, we did not find any significant differences for the
other splice variants studied, including exons 12, 14, and
17, exons 12, 15, and 17, or exons 12, 13, 14, and 17
(Supplemental Table 2).
Figure 1. Differential expression of TCF7L2 splice variants and protein levels. A, Structure of the TCF7L2 gene. White bars indicate exons. Dark
gray bars indicate alternatively spliced exons. Arrow show primer localization within the gene (exon-exon junction), and dashed lines indicate
alternative splicing products. B–J, Graphical representations of the TCF7L2 mRNA levels for the 4 groups studied: nondiabetic C/C (white bar with
black circles), nondiabetic T/T (light-gray bar with black squares), diabetic C/C (dark-gray bar with white circles), and diabetic T/T (black bar with
white squares), where the y-axis represents the relative expression of the analyzed splice variants of TCF7L2 in arbitrary units (AU). Shown are
exclusion (B) and inclusion (C) of exon 4, extra nucleotides at the end of exon 7 exclusion (D) and inclusion (E), 12 extra nucleotides at the
beginning of exon 9 exclusion (F) and inclusion (G), and 3 end splice variants: variant containing exons 11, 12, and 17 (H), variant containing all
exons except 16 and 17 (I), and variant including exons 12, 13, and 17 (J). K, Representative Western blot for each group. L, Quantification of
TCF7L2 protein, normalized by actin. Values are means  SEM, representative of 2 independent experiments. 
, P  .05 and 

, P  .01 vs C/C
nondiabetic; #, P  .05 and ##, P  .01 vs C/C diabetic; *, P  .05, **, P  .01, and ***, P  .001 between nondiabetic and diabetic T/T carriers.
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In addition to the differential expression of the
TCF7L2 splice variants, we analyzed the protein levels,
because it has been reported that TCF7L2 protein expres-
sion levels in the at-riskT/T carriers are lower than inC/C
carriers. Our results show that protein expression was
statistically decreased in T2D patients carrying the at-risk
T/T genotype (P 	 .008 vs C/C T2D) and was also re-
duced in nondiabetic individuals carrying the at-risk T/T
genotype (P	 .051 vs C/C non-T2D) (Figure 1, K and L,
and Supplemental Table 2).
TRA2B regulation of the TCF7L2 exon 4
alternative splicing
Next, we aimed to investigate the cause for the differ-
ential TCF7L2 splicing patterns, focusing our efforts on
exon 4, since its splicing was significantly enhanced or
repressed in both groups carrying the at-risk T/T geno-
type. Based on the in silico analysis of the binding sites of
the splicing factor for TCF7L2 exon 4 and the surround-
ing introns, we studied the heterogeneous nuclear ribonu-
cleoprotein hnRPA1 and the expression of the alternative
splicing factors SFRS7 and TRA2B (also known as
SFRS10), taking into account the fact that TRA2B is an
autoregulated splicing factor (31).
Interestingly, the expression analysis of the hnRPA1
gene showed that nondiabetic individuals and T2D pa-
tients carrying the at-risk T/T genotype did not behave
differently, because the gene is statistically significant de-
creased in both (P	 .002 vs C/C non-T2D and P	 .028
vs C/C T2D) (Figure 2A and Supplemental Table 3). On
one hand, the alternative splicing factor SFRS7 showed
significant differences between nondiabetic individuals
and T2D patients carrying the at-risk T/T genotype.
SFRS7 expression was increased in nondiabetic individu-
als (P	 .038 vsC/C non-T2D), whereas it was reduced in
T2D patients (P 	 .031 vs C/C T2D) (Figure 2B and
Supplemental Table 3). On the other hand, the qRT-PCR
results showed clear regulation of the alternative splicing
factor TRA2B in T2D patients carrying the at-risk T/T
genotype, with a significant increase in functional splice
variant 1 (TRA2B-1, P	 .046 vs C/C T2D) and a signif-
icant decrease in variant 4 (TRA2B-4, P 	 .023 vs C/C
T2D), which is not translated into protein (Figure 2, C
and D, respectively, and Supplemental Table 3). There-
fore, the ratio TRA2B-1/TRA2B-4 (Figure 2E) was lower
than 1 in nondiabetic individuals carrying the at-risk T/T
genotype, whichwas the group that excludesmore exon 4
in TCF7L2. However, in T2D patients carrying the at-
Figure 2. Down-regulation of alternative splicing factors in T2D risk-associated genotype carriers. Graphical representation of the relative
expression of the genes encoding different splicing factors for the four studied groups: nondiabetic C/C (white bar with black circles), nondiabetic
T/T (light-gray bar with black squares), diabetic C/C (dark-gray bar with white circles), and diabetic T/T (black bar with white squares), where the
y-axis represents the relative expression of the analyzed genes in arbitrary units (AU). Regulation of the heterogeneous nuclear ribonucleoprotein
hnRPA1 (A), the alternative splicing factors SFRS7 (B), and TRA2B variant 1 (C) and variant 4 (D). E, Graphical bar representation of the ratio of the
functional variant TRA2B-1 and nonfunctional TRA2B-4. Values are means  SEM, representative of 2 independent experiments. 
, P  .05 and


, P  .01 vs C/C nondiabetic; #, P  .05 and ##, P  .01 vs C/C diabetic; *, P  .05, **, P  .01, and ***, P  .001 between nondiabetic and
diabetic T/T carriers.
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risk T/T genotype, who had increased inclusion of
TCF7L2 exon 4, the ratio was higher than 1, meaning
that in the second group there was a higher amount of
TRA2B-1 mRNA, which was able to translate into func-
tional protein.
Taking into account these interesting results and also
the facts that the in silico analysis showed that TRA2B
was the main transcription factor in this locus and that it
has binding sites close to the SNP rs7903146, we decided
to study whether TRA2B is an essential alternative splic-
ing factor of TCF7L2 exon 4. To address this hypothesis
we silenced TRA2B in control nondiabetic individuals
carrying the C/C genotype and studied whether this si-
lencing was able to alter the splicing of TCF7L2 exon 4.
We found that the in vitro TRA2B silencing showed a
significant reduction of both isoforms (TRA2B-1, P 	
.0006 andTRA2B-4, 68% P	 .0006) (Figure 3, A and B,
respectively, and Supplemental Table 4), triggering a sig-
nificant decrease in TC7L2 exon 4 exclusion (P	 .0041)
and a significant increase in exon 4 inclusion (P	 .0006)
(Figure 3, C and D, and Supplemental Table 4).
Given that these results shed some light on the possible
mechanism but the main question remains still to be an-
swered, we think that the regulation of this differential
expression of the alternative splice variant could be due to
an environmental risk factor, such as high levels of insulin
(32, 33) or glucose. For this reason, we assessed the ex-
pression levels of TRA2B in an in vitro cell culture of
control nondiabetic individuals carrying the C/C geno-
type with a high concentration of glucose (25 mM) or
insulin (100 nM). Interestingly, the expression levels of
TRA2B were significantly decreased under hyperglyce-
mic and hyperinsulinemic conditions (P 	 .015 and P 	
.018 vs untreated C/C non-T2D, respectively) (Figure 3E
and Supplemental Table 4).
ER stress pathways and translational regulation
of TCF7L2
Proteins requiring posttranslational modifications are
processed in the ER. Different cellular scenarios can lead
to a dysfunction of the ER and ultimately to an imbalance
between the protein-folding capacity and load, triggering
ER stress. The first step is that the unfolded or misfolded
proteins are tagged for degradation via the endoplasmic re-
ticulum–associated degradation (ERAD) pathway. How-
Figure 3. TRA2B silencing and TCF7L2 exon 4 splicing. Graphical bar representation of the TRA2B splice variant 1 (A) and splice variant 4 (B)
siRNA silencing and the corresponding expression levels of TCF7L2 exon 4 exclusion (C) and inclusion (D). Nondiabetic C/C individuals treated with
non-targeting pool siRNA (white bar with black circles) and nondiabetic C/C individuals treated with TRA2B smart pool siRNA (black bar with white
circles), where the y-axis represents the relative expression in arbitrary units (AU). E, Graphical bar representation of TRA2B expression including
control (white bar with black rhombus), hyperglycemic (25 mM; white bar with white triangle), and hyperinsulinemic (100 nM; white bar
with inverted white triangle) conditions. Values are means  SEM, representative of 2 independent experiments. *, P  .05, **, P  .01,
and ***, P  .001.
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ever, if incorrectly folded proteins continue to accumu-
late, the UPR is triggered and induces apoptosis.
As our earlier results showed, TCF7L2 presented a gen-
otype-dependent differential expression of the TCF7L2
splicing pattern in lymphocytes. The characterization of
proapoptotic splice variants and the reduced protein lev-
els in T2D patients carrying the at-risk T/T genotype
might suggest the involvement of ER stress, thus trigger-
ing apoptosis in these T2D patients. Hence, we studied
the expression and protein levels of several genes encod-
ing the principal proteins involved in the UPR.
First, we analyzed the expression of the gene encoding
the chaperone BiP (also known as GRP78). During adap-
tation, the UPR tries to reestablish a folding homeostasis
by inducing the expression of chaperones that enhance
protein folding. We found a significant increase in non-
diabetic individuals and T2D patients carrying the at-risk
T/T genotype (P	 .035 vsC/C non-T2D and P	 .002 vs
C/C T2D), suggesting that ER stress could be associated
with the T2D risk–associated genotype (Figure 4A and
Supplemental Table 5).
Second, we studied the 3 different pathways involved
in the UPR. Initially we analyzed the pathway mediated
by the transmembrane PERK. The results showed an up-
regulation of PERK, ATF4, CHOP, and BIM genes (pro-
apoptotic) acting at different levels of the apoptosis path-
way in T2D patients carrying the at-risk T/T genotype
(P	 .014, P	 .011, P	 .007, and P	 .017 vsC/C T2D,
respectively) (Figure 4, B and E–G, respectively, and Sup-
plemental Table 5). Accordingly, the antiapoptotic gene
BCL2 was down-regulated (P 	 .012 vs C/C T2D) (Fig-
ure 4 H and Supplemental Table 5).
We next analyzed the pathway that was mediated by
IRE1. This pathway presents 2 different branches. The
Figure 4. Expression of the ER stress genes. Panels show the graphical representation of the mRNA levels of the main genes involved in the ER
stress pathways for the 4 groups studied: nondiabetic C/C (white bar with black circles), nondiabetic T/T (light-gray bar with black squares),
diabetic C/C (dark-gray bar with white circles), and diabetic T/T (black bar with white squares), where the y-axis represents the relative expression
of the analyzed genes in arbitrary units (AU). Shown are the chaperone BiP (A) and the 3 transmembrane receptors PERK (B), IRE1 (C), and ATF6
(D), its downstream genes ATF4 (E), CHOP (F), BIM (G), BCL2 (H), TRAF2 (I), ASK1 (J), JNK (K), XBP1sp (L), and EDEM 1 (M), EDEM2 (N), and EDEM3
(O). Values are means  SEM, representative of 2 independent experiments. 
, P  .05 and 

, P  .01 vs C/C nondiabetic; #, P  .05 and
##, P  .01 vs C/C diabetic; *, P  .05, **, P  .01, and ***, P  .001 between nondiabetic and diabetic T/T carriers.
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first branch is mediated by the adaptor protein, TNF re-
ceptor–associated factor 2 (TRAF2), which activates the
c-Jun NH2-terminal kinase (JNK) through the apoptosis
signal–regulating kinase (ASK1), leading to apoptosis. In
this branch, all these proapoptotic genes were up-regu-
lated in T2D patients carrying the at-risk T/T genotype
(TRAF2, P 	 .006, ASK1, P 	 .038, and JNK, P 	 .014
vsC/CT2D) (Figure 4, C, I–K and Supplemental Table 5).
The other branch is headed by X-box binding protein 1
(XBP1), which is spliced under ER stress, and the spliced
isoform induces degradation via the ERAD pathway. Sur-
prisingly, the spliced XBP1 was up-regulated in control
nondiabetic individuals carrying the at-risk T/T genotype
(P 	 .012 vs C/C non-T2D), whereas it remained un-
changed in T2D patients carrying the at-risk T/T geno-
type. The spliced XBP1 results suggest that the nondia-
betic individuals carrying the at-risk T/T genotype could
be directed to the ERAD pathway instead of being di-
rected to apoptosis (Figure 4L and Supplemental Table 5).
To get a complete view of the ER stress pathway, we
studied the ATF6 pathway, which showed an up-regula-
tion of this gene in nondiabetic individuals carrying the
at-risk T/T genotype (P 	 .014 vs C/C non-T2D) that
finally leads to ERAD (Figure 4D and Supplemental Table
5). Because of the up-regulation of the genes involved in
ERAD in control individuals carrying the at-risk T/T ge-
notype, we analyzed the genes encoding 3 ER degradation
enhancers (EDEM1, EDEM2, and EDEM3) and found
that they were also up-regulated (P	 .007, P	 .006, and
P	 .014 vs C/C non-T2D, respectively) (Figure 4, M, N,
and O, and Supplemental Table 5).
In addition to the differential mRNA expression of the
genes involved in the ER stress pathway, we checked the
protein levels of some of them. The protein levels of BiP
(P 	 .021, T/T non-T2D vs C/C non-T2D and P 	 .003,
T/T T2D vs C/C T2D), phospho-eIF2 (mediator of the
PERK branch) (P	 .004,T/TT2D vsC/C non-T2D), and
CHOP (P 	 .004, T/T T2D vs C/C non-T2D) correlated
with the previous mRNA expression results (Figure 5,
A–D, and Supplemental Table 6).
Finally, apoptosis can also be measured by caspase
activity and to confirm our previous results, we analyzed
caspase activity using the Caspase-Glo 3/7 assay. Our
results showed an increase of at least 1.7-fold in the
caspase activity in T2D patients carrying the at-risk T/T
genotype (P 	 .010 vs C/C T2D, P 	 .003 vs C/C non-
Figure 5. Protein levels of the ER stress response and caspase activity. A, Representative Western blots for the 4 groups studied: nondiabetic C/C
(white bar with black circles), nondiabetic T/T (light-gray bar with black squares), diabetic C/C (dark-gray bar with white circles), and diabetic T/T
(black bar with white squares), where the y-axis represents the relative quantification of the analyzed proteins. Quantification of protein levels of
BIP (B), phospho (p)-eIF2 (C), and CHOP (D). E, Caspase 3/7 activity measured as relative light unit. Values are means  SEM, representative of 2
independent experiments. 
, P  .05, and 

, P  .01 vs C/C nondiabetic; #, P  .05 and ##, P  .01 vs C/C diabetic; *, P  .05 and **, P 
.01 between nondiabetic and diabetic T/T carriers.
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T2D, and P 	 .021 vs T/T non-T2D) (Figure 5E and
Supplemental Table 6).
Discussion
SNPs in the TCF7L2 gene (previously known as TCF4)
have been shown to be strong genetic risk factors for T2D
(3). The polymorphism with the strongest risk is the in-
tronic SNP, rs7903146 (T/T); this SNP presents a T2D
risk-associated genotype that is present in only 7%–10%
of nondiabetic individuals but increases up to 14%–20%
in T2D patients (3–5). During the last few years, efforts to
understand the role of TCF7L2 in the development of
T2D have increased, and it has been shown that TCF7L2
confers T2D risk mainly through impaired insulin secre-
tion, perturbed incretin effect, and reduced  cell survival
(34). In diabetes, TCF7L2mRNA is up-regulated in pan-
creatic islets, reducing glucose-stimulated insulin secre-
tion, but TCF7L2 protein levels are down-regulated. One
possibility for this controversial finding is that the in-
creased mRNA expression represents multiple possible
splice variants of TCF7L2, which encode many different
isoforms with different effects on target cells.
Genetic variations may affect the levels of gene expres-
sion and splicing architecture of pre-mRNA transcripts,
thus increasing the risk of development of a specific dis-
ease (3). In this regard, extensive work has been done to
evaluate the splicing diversity ofTCF7L2 in a broad range
of human and mouse cell lines and tissues, including not
only pancreatic islets but also liver, gut, muscle, brain,
and adipose tissues, among others (7–13, 15). Although
several studies have revealed that TCF7L2 presents a tis-
sue-specific splicing pattern, most of these studies found
no association between the splicing pattern and the T2D
risk-associated T/T genotype. In this direction, Prokunina-
Olsson et al (7) suggested an association of rs7903146 with
the3 end splicing variants inpancreatic islets, pancreas, and
colon (7), and Mondal et al (15) also found an association
between the rs7903146 genotype and the 3 end splicing
variants in adipose tissue, but the statistical significance was
lost after correction with multiple tests in both studies.
Taking into account the fact that opposite regulation
of TCF7L2 mRNA and protein levels exists in T2D (14,
27), we hypothesized that this opposite regulation be-
haves differently between nondiabetic individuals and
T2D patients carrying the C/C or the at-risk T/T geno-
type. To address our hypothesis, we defined 4 study
groups: nondiabetic individuals carrying (1) the nonrisk
C/C genotype or (2) the at-risk T/T genotype and T2D
patients carrying (3) the nonrisk C/C genotype or (4) the
at-risk T/T genotype.
The ideal scenario to address our hypothesis would
have been to study pancreatic  cells, which are the key-
stone cells in diabetes, because of their failure to compen-
sate for high glucose levels in blood and initiation of the
development of T2D. Considering the extremely low
availability of human pancreas donors and the low fre-
quency of this SNP in the population, we investigated
splicing patterns in immortalized B lymphocytes. These
cell lines have been extensively used as a source of biolog-
ical material for functional and molecular studies and
represent a potentially limitless source of genomic DNA,
RNA, and protein. More precisely, in the scope of a study
with an alternative splicing landscape (35–37), lympho-
cytes have been used as a reliable source. Indeed, it has
been reported previously that pancreatic islets and blood
have similarTCF7L2 splicing patterns (7, 12), pointing to
lymphocytes as a representative source for the study of
alternative splicing. Osmark et al (12) reported that
TCF7L2 presents a tissue-specific expression pattern for
exon 15, which is preferred in blood and islets, as well as
for exon 4, which is retained principally in islets (60%)
but is also retained in blood (35%). In their study, they
did not observe a significant effect of the rs7903146 ge-
notype on the splicing pattern, but interestingly they
based this study on tissue samples from nondiabetic indi-
viduals exclusively, and, more remarkably, no individuals
were homozygous for the risk T allele (12). Although
immortalized B lymphocytes represent a convenient op-
tion to study a system in which one is not reliant on fresh
tissue and experiments can be repeated consistently and
this cell type has shown an alternative splicing pattern
similar to that in pancreatic islets, we should be cautious
when extrapolating results from lymphocytes to a plausi-
ble mechanism in pancreatic  cells. Lymphocytes cannot
replace the  cell; however, lymphocytes could mirror
some of the pathways and processes underlying the mo-
lecular mechanism, which explain how the TCF7L2 ge-
netic variation leads to altered biological functions in
pancreatic  cells.
Our results showed increased inclusion of exon 4 in
T2D patients carrying the at-risk T/T genotype, contrary
to the increased exclusion of the same exon in nondiabetic
individuals carrying the same at-risk genotype. Down-
stream we also found a different pattern for the extra
nucleotides splicing into exon 7 and for the previously
described 3 end splicing variants. Interestingly, in 2011,
Le Bacquer et al (13) described in human pancreatic 
cells from nondiabetic pancreas donors, who did not
carry the at-risk genotype, the presence of one proapop-
totic TCF7L2 splice variant (including exon 4 and skip-
ping exons 13 to 16) and 2 other protective variants (that
differed in the 3 end splicing). We propose that in at-risk
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T/T genotype carriers the T2D patients overexpressed the
proapoptotic splice variant, whereas the control individ-
uals overexpressed the protective splice variants. These
results are a novel step in the understanding of the mo-
lecular mechanism that differs from the association
between the SNP and T2D, because it points out the pos-
sibility of development of T2D in individuals with the
at-risk T/T genotype but not in nondiabetic carriers.
Once we identified differential expression of TCF7L2
splice variants between nondiabetic individuals and T2D
patients carrying the at-risk T/T genotype and because
several previous studies have been focused on the
TCF7L2 3 end splicing pattern, but no clear correlation
between the splicing and the rs7903146 has been found,
we focused our research on understanding the alternative
splicing of exon 4. The in silico analysis of exon 4 and the
intronic sequence surrounding rs7903146 showed an en-
richment of several putative binding sites corresponding
to a few splicing factors. Thus, we determined by qRT-
PCR the expression levels of the alternative splicing fac-
tors TRA2B and SFRS7 and the heterogeneous nuclear
ribonucleoprotein hnRPA1, which had been shown pre-
viously by in silico analysis to bind to exon 4 and its
surrounding intronic sequence. TRA2B is an SR-like pro-
tein that tightly autoregulates its own concentration by
influencing the alternative splicing of its pre-mRNA (31).
The proper concentration of TRA2B is important, since
several pathological states are associated with changes in
this concentration (32). In brief, the functional splice vari-
ant 1 (skips exon 2) encodes the protein TRA2B-1, which
regulates the inclusion of its own exon 2. This inclusion of
exon 2 generates mRNA (the nonfunctional splice variant
4 TRA2B-4) that is not translated into protein, so the
proportion of both variants is important to keep the
proper concentration of the TRA2B-1 protein.
We found differences in expression levels between
non-T2D individuals and T2D patients carrying the at-
risk T/T genotype. Nondiabetic individuals showed nor-
mal expression levels of TRA2B-4 and down-regulation
of TRA2B-1, but, surprisingly, in T2D patients the results
indicated a clear autoregulation of these splice variants.
We found significant up-regulation in the expression of
TRA2B-1 and significant down-regulation of TRA2B-4,
keeping the ratio between the functional and nonfunc-
tional isoforms (TRA2B1/TRA2B4) greater than 1 in
T2D patients and lower than 1 in nondiabetic control
individuals. When TRA2B was silenced in vitro in nondi-
abetic individuals carrying the C/C genotype, the exclu-
sion of TCF7L2 exon 4 was decreased, whereas the in-
clusion of exon 4 was increased. All of this information
suggests that TRA2B plays an essential role, at least in
human immortalized lymphocytes, in the splicing of
TCF7L2 exon 4.
Thus, we should consider the possibility that the nat-
ural development of T2Dwith increasing levels of glucose
and insulin could be responsible for the changes in expres-
sion of the alternative splicing factors (32). Hence, differ-
ent splice variants between nondiabetic controls and T2D
patients are generated, as we have noted, finding a statis-
tical reduction in TRA2B expression under hyperglyce-
mic or hyperinsulinemic conditions. We should also take
into account the fact that TRA2B is a splicing factor with
complex autoregulation, and, as we proposed, the ratio
between the functional and nonfunctional variants could
be the keystone for the splicing of TCF7L2 exon 4.
Furthermore, it is noteworthy that prior exposure to a
poor metabolic environment could have generated a det-
rimental “metabolic memory”, as has been described pre-
viously (38–43), including lymphocytes (44). This phe-
nomenon has been replicated in animals and in several
cellular models, indicating that expression patterns allow
a quick response to changing environmental stimuli but at
the same time confer to the cell the ability to “memorize”
these encounters, deriving self-perpetuating modifica-
tions of gene expression patterns (45). Finally, we should
keep in mind not only that the spliceosome machinery
recognizes one specific exon along the TCF7L2 gene but
also that the spliceosome is built up of different constitu-
tive and alternative splicing factors and TRA2B is just one
of them.
Once we described the alternative splicing of TCF7L2
exon 4, we focused our research on understanding the
mechanisms underlying the posttranslational regulation
of TCF7L2, in which protein levels are reduced in the
at-risk genotype carriers. We considered that when these
different splice variants are translated into proteins which
are finally processed and folded in the ER, the ER faces
some problems in proper folding of this variety of pro-
teins. This process could trigger apoptosis through the
UPR. Thus, we studied several genes implicated in the ER
stress pathway and found that 2 different branches were
overexpressed in the at-risk T/T genotype carriers, de-
pending on whether they have developed T2D or not. On
one hand, in nondiabetic individuals, the expression of
ATF6 and IRE1, through XBP1 branches, was increased
flowing into ERAD, including up-regulation of EDEM1,
EDEM2, and EDEM3. On the other hand, in T2D pa-
tients the expression of PERK and IRE1, throughTRAF2
branches, was augmented. However, in this case, the up-
regulation of the downstream genes, except for the anti-
apoptotic BCL2, was associated with an increase in apo-
ptosis, fitting with our previous results showing an
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overexpression of the proapoptotic splice variant in T2D
risk-associated genotype carriers (Supplemental Figure 2).
Based on the in silico and experimental data results, we
speculate that the at-risk T/T genotype from the SNP
rs7903146 inTCF7L2 intron 4 could interact with an ISE
recognized by the SR protein TRA2B, modulating the
alternative splicing of TCF7L2 exon 4. In addition,
TRA2B not only recognizes this ISE but also recognizes
ESEs in exon 4, which also promotes the inclusion of
TCF7L2 exon 4 (Supplemental Figure 3). In this hypo-
thetical scenario, SFRS7 and hnRPA1 could also be in-
volved in orchestrating the alternative splicing of
TCF7L2 exon 4. Taking this information into account,
individuals carrying the C/C genotype (nondiabetic indi-
viduals and T2D patients) would not present interactions
between TRA2B and the ISE. Therefore, regarding exon
4, they could be compensating between the enhanced
exon 4 inclusion from TRA2B and the inhibited inclusion
from SFRS7, with a final readout of a compensatory re-
sponse between inclusion and exclusion (Supplemental
Figure 3A). Alternatively, nondiabetic individuals carry-
ing the at-risk T/T genotype could present interactions
between TRA2B and the ISE. Therefore, regarding exon
4, SFRS7 presents higher expression than TRA2B, al-
though a lower level of hnRPA1 would help to increase
the exclusion of exon 4 (Supplemental Figure 3B). Finally,
T2D patients carrying the at-risk T/T genotype could
present a stronger interaction between TRA2B and the
ISE (reinforced under diabetic conditions), and regarding
exon 4, SFRS7 and hnRPA1 could present lower expres-
sion levels than TRA2B, which also binds tightly to the
ISE, finally increasing the inclusion of exon 4 (Supple-
mental Figure 3C).
In summary, this study shows, for the first time, differ-
ences in the expression of the different TCF7L2 splice
variants in at-risk T/T genotype carriers that distinguish
between nondiabetic and T2D patients. These differences
are marked at the exon 4 splicing, indicating increased
exclusion in T2D patients and increased inclusion in non-
diabetic individuals carrying the at-risk T/T genotype.
These splicing differences could be explained by the au-
toregulation of the alternative splicing factor TRA2B,
which at the same time is regulated by glucose and insulin.
The distribution of the splice variants is associatedwith pre-
viously described protective and proapoptotic TCF7L2
splice variants. This association and the reduced protein
levels found in at-risk T/T genotype carriers directed our
study on ER stress. Our results suggest that the TCF7L2
splice variants activate specific ER stress pathways in
nondiabetic individuals and T2D patients carrying the
at-risk T/T genotype, driving the increased apoptosis in
T2D patients.
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